![](/images/graphics-bg.png)
Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi)
Joint Authors
Chang Muñoz, Meilen
Murphy, Jennifer A.
Wolff, Johannes E.
Jonas, Brian A.
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-12-16
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Acute myeloid leukemia (AML) is an aggressive clonal bone marrow cancer characterized by high rates of relapse and mortality.
A middle-aged woman with AML relapsed twice after achieving complete remission with induction therapy and subsequent salvage therapy.
She was then enrolled in a clinical trial with the bromodomain extraterminal inhibitor (BETi) mivebresib and achieved complete remission with incomplete count recovery (CRi) with monotherapy.
Subsequently, she relapsed and was transitioned to combination therapy with mivebresib plus venetoclax and achieved CR again.
The patient required eltrombopag to decrease platelet dependence in both arms of the trial and exhibited less myelosuppression with the combination therapy.
The exceptional response to mivebresib demonstrated by this patient underscores the therapeutic potential of mivebresib.
American Psychological Association (APA)
Chang Muñoz, Meilen& Murphy, Jennifer A.& Wolff, Johannes E.& Jonas, Brian A.. 2020. Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi). Case Reports in Hematology،Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1147812
Modern Language Association (MLA)
Chang Muñoz, Meilen…[et al.]. Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi). Case Reports in Hematology No. 2020 (2020), pp.1-6.
https://search.emarefa.net/detail/BIM-1147812
American Medical Association (AMA)
Chang Muñoz, Meilen& Murphy, Jennifer A.& Wolff, Johannes E.& Jonas, Brian A.. Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi). Case Reports in Hematology. 2020. Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1147812
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1147812